Reuse of Single Use Devices CDRH/CBER MDUFMA Stakeholder Meeting Presented by: Barbara Zimmerman.

Slides:



Advertisements
Similar presentations
Validating Sterilization of Medical Devices
Advertisements

Device Initiatives FY 2005 Karen A. Coleman FDA Device National Expert.
Overview of FDA Device Regulations
"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
Strengthening the Medical Device Clinical Trial Enterprise
1 High Production Volume (HPV) Challenge Program – Future Directions Jim Willis Director, Chemical Control Division, Office of Pollution Prevention and.
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
510k Submission Overview Myraqa, Inc. August 22, 2012.
Medical Devices Approval Process
Pre-Market and the QSR Presented by: Dawn Fernandes.
External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.
Manufacturer’s Instructions
CBER Managed Review Process Sheryl A. Kochman Deputy Director, DBA, OBRR, CBER September 15, 2009.
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Weaving regulations into sound value analysis processes Barbara Strain, MA, SM(ASCP) Director Value Management University of Virginia Health System.
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
DRAFT Guidance for Industry: Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing Denise Sánchez, J.D.,
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Premarket Review Performance Goals Patricia B. Shrader BD November 18, 2004.
Slide 1 of 22 Rob Packard, President 510(k) Project Management.
Experiences with registrations - 5 years on the road On the REACH Road 23 November 2011 Kevin Pollard ECHA – Dossier Submission and Dissemination.
ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Primacy Revision Application The Arsenic Rule. Major Points Components of Primacy Revision Application Attorney General’s Statement Special Primacy Requirements.
Understanding the Pre-IDE Program: FDA Perspective
Product Development Chapter 6. Definitions needed: Verification: The process of evaluating compliance to regulations, standards, or specifications.
Bloodborne Pathogens 29 CFR Components of the Standard Exposure Control Plan Methods of Compliance –Universal Precautions –Engineering and.
OIVD Workshop Premarket Notification (510(k)) April 22, 2003 Parklawn Building Rockville, MD Presented by Marjorie Shulman Premarket Notification Staff.
1 CONSENSUS STANDARDS OIVD WORKSHOP April 22-23, 2003 Rockville MD Ginette Y. Michaud, M.D. OIVD.
Kimberly A. Trautman FDA’s Medical Device Quality System Expert
New Draft Guidance for Multiplex Tests Elizabeth Mansfield and Michele Schoonmaker Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) CDRH/FDA.
510(k) Submissions Recent Experience and Perspectives Terry Sullivan Vice President, Regulatory Affairs.
Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.
1 Combination Products: Jurisdictional Issues MassMEDIC Presentation March 28, 2006 Janice Hogan, Esq. Partner Hogan & Hartson, LLP
Rigid Plastic Packaging Container (RPPC) Informational Update Permitting and Compliance Committee Meeting February 17, 2009.
1 Medical Device User Fee and Modernization Act (MDUFMA II) Legislative Recommendations April 30, 2007.
Overview of FDA's Regulatory Framework for PET Drugs
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
REGULATION OF COMBINATION PRODUCTS Mark A. Heller Wilmer Cutler Pickering Hale and Dorr LLP MassMEDIC Combination Product Program, March 28, 2006.
Comparability Protocols Lore Fields MT(ASCP)SBB Consumer Safety Officer DBA/OBRR/CBER September 16, 2009.
1 BIORESEARCH MONITORING AND IN VITRO DIAGNOSTICS SYBIL WELLSTOOD, PH.D. OFFICE OF COMPLIANCE DIVISION OF BIORESEARCH MONITORING.
FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,
GU Advisory Panel Meeting Nocturnal Home Hemodialysis Draft Carolyn Y. Neuland, Ph.D. Chief, Gastroenterology and Renal Devices Branch Division of Reproductive,
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
Animal Raising Claims in the Labeling of Meat and Poultry Products October 14, 2008 United States Department of Agriculture Food Safety and Inspection.
BioUtah Pre-Submission Issues Workshop April 6, 2016 Ryan O’Callaghan Phil Triolo and Associates LC.
ITRI Industrial Technology Research Institute The Audit Process of Medical Device GMP for Domestic Manufacturers DOH Designated Auditing Organizations.
Device Updates in FDASIA MDUFA III RA SAIC – 9 th April 2013 Karen Jaffe, MS, MBA, RAC or
NANCY CHOBIN, RN, AAS, ACSP, CSPM, CFER CHOBIN & ASSOCIATES CONSULTING HOT TOPICS IN STERILIZATION AND DISINFECTION.
SteriTite Instructions for use
Device regulations USA Dr Phil Warner. USA Regulations MEDICAL DEVICES Food, Drug & Cosmetics Act Medical Device Amendments of 1976 (and other things)
United States Department of Agriculture Food Safety and Inspection Service Draft Labeling Policy Guidance for N- 60 Testing Claims for Boneless Beef Manufacturing.
Workshop on conformity assessment procedures and certification of medical devices INT MARKT Kyiv, November 2011 Conformity assessment of medical.
An agency of the European Union Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 0070 Principles Industry.
U.S. FDA Center for Devices and Radiological Health Update
Premarket Notification 510(k) process
FDA’s IDE Decisions and Communications
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
The Current PMA Requirements
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Cleaning Verification
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
ISO 9001:2015 Auditor / Registration Decision Lessons Learned
Sterilization September 2018.
יוסי שדמתי רק איכות מניהול סיכונים לאימות ותיקוף תהליכי הרכבה From Risk Management to Processes Validation יוסי.
Linda M. Chatwin, Esq. RAC Business Manager, UL LLC
Recommendations to facilitate assessment of new application procedures
Difficult to prevent reuse of single use devices
Online Course Change Request Submission
Online Course Change Request Submission
Presentation transcript:

Reuse of Single Use Devices CDRH/CBER MDUFMA Stakeholder Meeting Presented by: Barbara Zimmerman

Sec. 302 – Single-Use Medical Devices (SUDs) Certain reprocessed SUDs identified by FDA must include validation data. Validation data includes cleaning, sterilization, and functional performance data demonstrating substantial equivalence.

Requirements of Sec. 302 For reprocessed SUDs which are exempt from 510(k) requirements, determine which “critical” reprocessed SUDs are no longer exempt Federal Register notice- dated April 30, 2003 (List I) Federal Register notice- dated June 26, 2003 (added non-electric biopsy forceps to List I) Due date for validation data to be submitted to FDA – July 30 and Sept. 26, 2004

Requirements of Sec. 302 Determine which non-exempt reprocessed SUDs require validation data Federal Register notice- dated April 30, 2003 (List II) Due date for validation data to be submitted to FDA – January 30, 2004

Requirements of Sec. 302 For reprocessed SUDs which are exempt from 510(k) requirements, determine which “semi-critical” reprocessed SUDs are no longer exempt Federal Register notice- dated April 24, 2004 (List I) Due date for 510(k)s with validation data to be submitted to FDA – July 24, 2005

Comments Submitted to Docket Bundling of reprocessed SUDs Review Prioritization Scheme Update of Lists I and II to include additional devices Timeliness of FDAs review of validation data

SUPPLEMENTAL VALIDATION SUBMISSIONS for Reprocessed Single-Use Medical Devices (SUDs) Ginette Y. Michaud, MD Office of Device Evaluation November 18, 2004 Gaithersburg, Maryland

Supplemental Validation Submissions (SVSs) July 2003: guidance on the validation data to be submitted June of 2004, updated guidance with information on review timelines.

Supplemental Validation Submissions 53 SVSs anticipated accounting for 1800 device models 9 SVSs were not submitted – all NSE 44 SVSs received; 19 SE 12 SE for some models 11 NSE or withdrawn 2 under review

Supplemental Validation Submissions CDRH accounted for 1800 device models 52% found SE - may continue to be legally marketed 33% found NSE (no data or inadequate data submitted) 15% withdrawn by the reprocessor.

Supplemental Validation Submissions Reprocessed SUDs that were withdrawn or found NSE may no longer be legally marketed. Reprocessors of these SUDs may submit new 510(k) premarket notifications to FDA.

Supplemental Validation Submissions In completing MDUFMA mandate, CDRH: –accounted for 1800 SUD models –addressed complex scientific issues –resource intensive and interactive process –careful and thorough reviews –timely and scientifically grounded regulatory decisions

How can users access information on the status of their reprocessed SUDs? Users can determine which models are legally marketed and which ones are not. The status of previously cleared reprocessed SUDs appears on FDA’s Reuse website, at: (

REPROCESSING OF SINGLE USE DEVICES (SUDS) MDUFMA Stakeholder’s Meeting November 18, 2004 Steven Turtil, M.S. FDA/CDRH/ODE/DAGID/INCB

510(k) Data – Reprocessed SUDs With each application, data should be submitted and reviewed for: Cleaning Validation Cleaning Validation Sterilization Validation Sterilization Validation Functionality Testing Functionality Testing –No Standards –Standards Available –Guidance and Standards Available

How do we want to define “Clean” To allow for successful, subsequent sterilization steps. To limit to a minimum, the organic soil transfer from one patient to another. To prevent accumulation of residual soil (and to prevent the development of biofilms) after multiple cycles.

FDA Recommended Validation Data, Post-Simulated Use, for Cleaning of SUDs Body Contact Device Examples Blood PathOphthalmicTissueCompromised Skin EP Catheters Phacoemulsification Tips Biopsy Forceps, Arthroscopes, Fixation Devices Vascular Compression Devices (external) TEST TYPES Test soil to be selected and justified according to the intended use of the device Visual Inspection Total Protein Hemoglobin Carbohydrates Contrast Media (where appropriate) No Visible Soil

Table of Contents Cleaning Process: Instructions for technicians - highly variable between reprocessors. Cleaning Process Validation: What is it? –Artificial Soils and Simulated Use Protocols: How are you going to get the devices dirty? –Cleaning Validation Protocols: How are you going to test the Cleaning Process? –Test Protocols and Cleaning Endpoints And a summary of Sterility, Endotoxin and Detergent Residues

Cleaning Process Cleaning Instructions should specify: Point-of-Use Decontamination Disassembly, if possible Automated or Manual cleaning, or a combination – time, temperature, brushing duration, etc. Ultrasound – time, temperature, setting (high, medium, low) Detergents, Enzyme Detergents – time, temp., concentration, cycle limit (replenishing) Intermediate Rinse Steps – time, temp., particular water quality specifications.

Table of Contents Cleaning Process: Instructions - highly variable between reprocessors. Cleaning Process Validation: What is it? –Artificial Soils and Simulated Use Protocols: How are you going to get the devices dirty? –Cleaning Validation Protocols: How are you going to test the Cleaning Process? –Test Protocols and Cleaning Endpoints And a summary of Sterility, Endotoxin and Detergent Residues

Table of Contents Cleaning Process: Instructions - highly variable between reprocessors. Cleaning Process Validation: What is it? –Artificial Soils and Simulated Use Protocols: How are you going to get the devices dirty? –Cleaning Validation Protocols: How are you going to test the Cleaning Process? –Test Protocols and Cleaning Endpoints And a summary of Sterility, Endotoxin and Detergent Residues

Table of Contents Cleaning Process: Instructions - highly variable between reprocessors. Cleaning Process Validation: What is it? –Artificial Soils and Simulated Use Protocols: How are you going to get the devices dirty? –Cleaning Validation Protocols: How are you going to test the Cleaning Process? –Test Protocols and Cleaning Endpoints And a summary of Sterility, Endotoxin and Detergent Residues

Table of Contents Cleaning Process: Instructions - highly variable between reprocessors. Cleaning Process Validation: What is it? –Artificial Soils and Simulated Use Protocols: How are you going to get the devices dirty? –Cleaning Validation Protocols: How are you going to test the Cleaning Process? –Test Protocols and Cleaning Endpoints And a summary of Sterility, Endotoxin and Detergent Residues

Cleaning Process Validation Use of actual clinical contamination as well as simulated organic soil that represents intended clinical exposure. Simulation of worst case clinical use conditions: –Inoculation sites should be most difficult to clean –Duration of exposure should mimic worst case –Articulations/Flextures/Manipulations, etc. Worst case cleaning conditions. Use of actual clinical contamination as well as simulated organic soil that represents intended clinical exposure. Simulation of worst case clinical use conditions: –Inoculation sites should be most difficult to clean –Duration of exposure should mimic worst case –Articulations/Flextures/Manipulations, etc. Worst case cleaning conditions. Cleaning Validation Protocols should support and confirm the effectiveness of the Routine Cleaning Instructions and should include consideration of:

Cleaning Validation Protocols Should Include WORST CASE consideration of: Automated, Manual or a combination – time, temperature, brushing duration Ultrasound – time, temperature, setting (high, medium, low) Detergents, Enzyme Detergents – time, temp., concentration, cycle limit (replenishing). Intermediate Rinse Steps – time, temp., particular water quality specifications. Automated, Manual or a combination – time, temperature, brushing duration Ultrasound – time, temperature, setting (high, medium, low) Detergents, Enzyme Detergents – time, temp., concentration, cycle limit (replenishing). Intermediate Rinse Steps – time, temp., particular water quality specifications.

Cleaning Validation Protocols Compare Cleaning Instructions with Validation Protocols If instructions say “Sonication 20 – 25 min.,” then validation should be for 20 min. or less. Examples (note set-points, tolerances): If instructions say “Not to exceed 12 devices per cleaning load,” then validation should be performed with 12 devices, or more.

Test Protocols and Cleaning Endpoints Specify the endpoints of cleaning, and data should meet them – at the end of its use-life. Visual Inspection should be part of both the routine cleaning and the cleaning validation (yet realize the limitations: e.g., lumens). Extraction method should be validated. Test methods should be validated. Specify the endpoints of cleaning, and data should meet them – at the end of its use-life. Visual Inspection should be part of both the routine cleaning and the cleaning validation (yet realize the limitations: e.g., lumens). Extraction method should be validated. Test methods should be validated.

Sterilization Standards are available for validation methods. –ISO – Industrial Moist Heat –ISO – Ethylene Oxide Applicants should provide a “summary of the sterilization process design and validation activities.” Use of routine methods for evaluation of endotoxins on medical devices, for those devices required to be labeled as such. Testing should be conducted on final, sterilized product (as always). Standards are available for validation methods. –ISO – Industrial Moist Heat –ISO – Ethylene Oxide Applicants should provide a “summary of the sterilization process design and validation activities.” Use of routine methods for evaluation of endotoxins on medical devices, for those devices required to be labeled as such. Testing should be conducted on final, sterilized product (as always).

Bundling Reprocessing a group of closely related device models based on validation data for a “representative” worst case model. How was the worst case device selected? –Were all materials considered? –All geometric variances? –Is there validation data to support this? –Or a scientifically valid justification? An especially tricky issue: slight differences in materials may result in different surface characteristics, and unexpected consequences with regard to cleaning effectiveness. Bundling between different manufacturers’ products should be validated or scientifically justified, because device designs can be very dissimilar. Reprocessing a group of closely related device models based on validation data for a “representative” worst case model. How was the worst case device selected? –Were all materials considered? –All geometric variances? –Is there validation data to support this? –Or a scientifically valid justification? An especially tricky issue: slight differences in materials may result in different surface characteristics, and unexpected consequences with regard to cleaning effectiveness. Bundling between different manufacturers’ products should be validated or scientifically justified, because device designs can be very dissimilar.

MDUFMA STAKEHOLDERS MEETING Reuse of Single Use Devices Panel – Compliance Update November 18, 2004

Reprocessor Inspection Update - Hospitals Over 225 inspections conducted since 8/2000 Three types of Inspections: –Routine surveillance, i.e. f/u to hospital registration –“For Cause” i.e. f/u to informant reports – Sample of hospitals based on their responses to a contractor survey Findings: –Most hospitals were either not reprocessing or promised to discontinue –A few early inspections led to FDA correspondence; one Warning Letter and two untitled letters

Reprocessor Inspection Update – Third Party Firms  In the 1990s, there were reprocessing firms Earlier inspections commonly found GMP problems in validation, purchasing controls & component controls 17 Warning Letters have issued 2 injunctions were filed; both firms went out of business All currently registered firms (5) have been inspected; all recent inspections found in substantial compliance

Compliance Follow-up to NSEs and Withdrawals Calls made to all applicants (5 firms) to determine withdrawal plans for distributed product All applicants have withdrawn/are withdrawing product Inspection assignment developed to verify discontinuance of reprocessing Inspection to cover special concerns raised by Office of Device Evaluation, i.e. packaging Inspection assignments request review of validation for the firm’s key processes